Forte Biosciences (FBRX) Cash from Operations Growth (5y) (2021 - 2026)
Forte Biosciences (FBRX) Cash from Operations Growth (5y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
| 10 |
Forte Biosciences |
70.77 Mn |
12.55 Mn |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
-36.08% |
| Dec 31, 2025 |
-34.09% |
| Sep 30, 2025 |
-12.59% |
| Jun 30, 2025 |
-20.16% |
| Mar 31, 2025 |
-29.30% |
| Dec 31, 2024 |
-72.62% |
| Sep 30, 2024 |
-71.20% |
| Jun 30, 2024 |
-18.82% |
| Mar 31, 2024 |
17.72% |
| Dec 31, 2023 |
5.57% |
| Sep 30, 2023 |
-63.22% |
| Jun 30, 2023 |
12.64% |
| Mar 31, 2023 |
16.35% |
| Dec 31, 2022 |
20.61% |
| Sep 30, 2022 |
22.73% |
| Jun 30, 2022 |
28.47% |
| Mar 31, 2022 |
23.56% |
| Dec 31, 2021 |
14.30% |
| Sep 30, 2021 |
8.37% |
| Jun 30, 2021 |
12.74% |
